Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab

Archives of Dermatology

Volumn 144, Issue 9, 2008, Pages 1190-1194

  Paltiel, Michael ^a   Gober, Laura M ^b   Deng, April ^a   Mikdashi, Jamal ^a   Alexeeva, Irena ^a   Saini, Sarbjit S ^b   Gaspari, Anthony A ^a,c  

^a Department of Dermatology ^*  (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CLOBETASOL PROPIONATE; CORTICOSTEROID; ETANERCEPT; HLA B27 ANTIGEN; HYDROCORTISONE; IMMUNOGLOBULIN E; METHOTREXATE;

ADULT; ANKLE ARTHRITIS; ARTHRITIS; ARTICLE; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HISTAMINE RELEASE; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; KNEE ARTHRITIS; LEUKOCYTE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT FAILURE; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; BASOPHILS; DRUG HYPERSENSITIVITY; FEMALE; HISTAMINE RELEASE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNIZATION; INJECTIONS, SUBCUTANEOUS; LEUKOCYTES; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51949118790     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.9.1190     Document Type: Article

References (22)

1. Mease PJ, Gaffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356(9227):385-390.
2. Lipsky PE, van der Heijde DM, St Clair EW, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate In the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343(22):1594-1602.
3. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999:130(6): 478-486.
4. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis In patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
5. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter. open-label, extended-treatment trial. Arthri-Arthritis Rheum. 2003;48(1):218-226.
6. Brandt J, Khariouzov A, Listing J, et al. Six-month results of adouble-blind. placebo-controlled trial of etanercept treatment In patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667-1675.
7. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002:359(9313): 1187-1193.
8. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for Induction of remission In ulcerative colitis. Cochrane Database Syst Rev. 2006;3:CD005112.
9. Hanauer SB, Snadborn WJ, Rutgeersts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) In Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2) :323-333.
10. Keystone EC, Kavanaugh AF. Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400-1411.
11. Maini R, St Clair EW, Breedveld F, et al; ATTRACT Study Group. Infliximab (chi-meric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo In rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354(9194):1932-1939.
12. Zeltser R, Valle L, Tanck C, Molyst MM, Ritchlin C, Gaspari AA. Clinical, histo-logical. and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor [alpha] receptor: Fc fusion protein. Arch Dermatol. 2001 ;137(7):893-899.
13. Vasagar K, Vonakis BM, Gober LM, Viksman A, Gibbons SP Jr, Saini SS. Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy. 2006;36(6):770-776.
14. MacGlashan DW, Bochner BS. Adelman DC, et al. Down-regulation of Fc (epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-lgE antibody. J Immunol. 1997;158(3):1438-1445.
15. Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, MacGlashan DW Jr. The relationship between serum IgE and surface levels of FcεR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol. 2000;106 (3):514-520.
16. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Amgen; 2006.
17. Humira (adalimumab) [package Insert]. North Chicago, IL: Abbott Laboratories; 2002.
18. Kay AB. Allergy and allergic diseases. N Engl J Med. 2001 ;344{1):30-37,
19. Fiendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy In patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666-R676.
20. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis Induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol. 2007;34(2):380-385.
21. Sfikakis PP, lliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis Induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005:52(8):2513-2518.
22. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis In patients receiving anti-tumour necrosis factor agents. Ann Rheum Dis. 2006;65(12):1541-1544.